Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for ELGX
14.10
+0.29 (2.10%)
After Hours: 14.34 +0.24 (1.70%)
Jul 26, 6:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.77 - 14.19
52 week 6.51 - 14.60
Open 13.81
Vol / Avg. 317,055.00/1.09M
Mkt cap 1.14B
P/E     -
Div/yield     -
EPS -1.20
Shares 81.82M
Beta 0.69
Inst. own 111%
Aug 2, 2016
Q2 2016 Endologix Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 2, 2016
Q2 2016 Endologix Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 11, 2016
Endologix Inc Conference Call to Discuss the Positive Clinical Data from the Nellix EVAS FORWARD-IDE Study
Jun 7, 2016
Endologix Inc at Jefferies Healthcare Conference
Jun 2, 2016
Endologix Inc Annual Shareholders Meeting
May 27, 2016
Endologix Inc Annual Shareholders Meeting (Estimated)
May 10, 2016
Endologix Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Endologix Inc Earnings Call - Webcast
May 9, 2016
Q1 2016 Endologix Inc Earnings Release
May 5, 2016
Endologix Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -112.52% -32.83%
Operating margin -90.65% -34.51%
EBITD margin - -27.30%
Return on average assets -51.81% -17.41%
Return on average equity -160.33% -44.34%
Employees 619 -
CDP Score - -

Address

2 Musick
IRVINE, CA 92618-1631
United States - Map
+1-949-5957200 (Phone)
+1-949-6999622 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Officers and directors

John D. McDermott Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 54
Bio & Compensation  - Reuters
Vaseem Mahboob Chief Financial Officer, Corporate Secretary
Age: 47
Bio & Compensation  - Reuters
Michael V. Chobotov Ph.D. Chief Technology Officer
Age: 55
Bio & Compensation  - Reuters
David M. Jennings Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Amanda L. DePalma Vice President - Global Marketing
Age: 44
Bio & Compensation  - Reuters
Jose A. Lima Vice President - Quality
Age: 50
Bio & Compensation  - Reuters
Shari L. O'Quinn Vice President - Regulatory and Quality Affairs
Age: 43
Bio & Compensation  - Reuters
James E. Machek Vice President - Research and Development, Manufacturing, Irvine
Age: 59
Bio & Compensation  - Reuters
Joseph A. DeJohn General Manager - Asia/Pacific and Latin America
Age: 55
Bio & Compensation  - Reuters